ABX 464

Drug Profile

ABX 464

Alternative Names: ABX-464

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Splicos
  • Developer Abivax
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 08 Dec 2016 Abivax plans a phase I/II trial in Healthy volunteers and for HIV infections in Spain (NCT02990325)
  • 31 May 2016 Abivax completes a phase II clinical trial for HIV infections (Treatment-naive) in Mauritius and Thailand (NCT02452242) (PO)
  • 01 May 2016 Phase-II clinical trials in HIV infections (Treatment-experienced) in Belgium, France (PO) (NCT02735863) after May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top